Published in JAMA on March 02, 2009
IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog (2011) 2.99
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog (2010) 1.81
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis (2010) 1.70
Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds. PLoS One (2011) 1.43
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother (2010) 1.29
Evolution in health and medicine Sackler colloquium: The comparative genomics of viral emergence. Proc Natl Acad Sci U S A (2009) 1.16
Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res (2013) 1.11
Evolution in health and medicine Sackler colloquium: a public choice framework for controlling transmissible and evolving diseases. Proc Natl Acad Sci U S A (2009) 1.10
Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses. J Clin Microbiol (2010) 1.05
Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One (2010) 1.04
Phosphatidylglycerol suppresses influenza A virus infection. Am J Respir Cell Mol Biol (2011) 1.01
The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol (2010) 1.00
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev (2013) 0.98
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother (2014) 0.96
Antiviral strategies for pandemic and seasonal influenza. Viruses (2010) 0.95
Detecting patches of protein sites of influenza A viruses under positive selection. Mol Biol Evol (2012) 0.95
Pathogen-host-environment interplay and disease emergence. Emerg Microbes Infect (2013) 0.95
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat Commun (2014) 0.91
Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis. Antimicrob Agents Chemother (2011) 0.86
The timing and targeting of treatment in influenza pandemics influences the emergence of resistance in structured populations. PLoS Comput Biol (2013) 0.86
The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Res (2011) 0.85
Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1. Am J Physiol Lung Cell Mol Physiol (2014) 0.82
Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction. PLoS One (2014) 0.80
Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden. PLoS One (2014) 0.80
Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors. ACS Med Chem Lett (2011) 0.79
A rigid bicyclic platform for the generation of conformationally locked neuraminidase inhibitors. Org Lett (2012) 0.78
Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations. Proc Natl Acad Sci U S A (2010) 0.78
Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales. PLoS One (2013) 0.77
Modeling the global transmission of antiviral-resistant influenza viruses. Influenza Other Respir Viruses (2013) 0.77
The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients. Sci Rep (2017) 0.75
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA (2009) 5.84
Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA (2009) 1.79
Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA (2009) 1.74
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A (2009) 2.73
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. Mol Cell (2008) 2.28
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell (2009) 2.12
Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med (2003) 2.09
A multicenter intervention to prevent catheter-associated bloodstream infections. Infect Control Hosp Epidemiol (2006) 1.93
The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. J Cell Biol (2010) 1.80
Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant (2007) 1.77
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep (2011) 1.60
Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis (2004) 1.56
Data requirements for electronic surveillance of healthcare-associated infections. Infect Control Hosp Epidemiol (2014) 1.53
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One (2013) 1.32
Adamantane resistance in influenza A. JAMA (2006) 1.25
Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection. Clin Infect Dis (2008) 1.24
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood (2009) 1.13
TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol Cell Proteomics (2012) 1.04
Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop. Stem Cells (2009) 1.03
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov (2011) 1.02
Effect of implementing safety-engineered devices on percutaneous injury epidemiology. Infect Control Hosp Epidemiol (2004) 1.01
Preventing catheter-associated bloodstream infections: a survey of policies for insertion and care of central venous catheters from hospitals in the prevention epicenter program. Infect Control Hosp Epidemiol (2006) 0.99
Allocation of scarce resources after a nuclear detonation: setting the context. Disaster Med Public Health Prep (2011) 0.99
Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice. Mol Cell Biol (2013) 0.98
Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood (2012) 0.97
Incomplete care--on the trail of flaws in the system. N Engl J Med (2011) 0.96
PARP1 is required for chromosomal translocations. Blood (2013) 0.96
TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database (Oxford) (2014) 0.93
The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood (2012) 0.92
Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. PLoS One (2011) 0.91
Triage and treatment tools for use in a scarce resources-crisis standards of care setting after a nuclear detonation. Disaster Med Public Health Prep (2011) 0.89
Pseudo-outbreak of multidrug-resistant Mycobacterium tuberculosis associated with presumed laboratory processing contamination. Infect Control Hosp Epidemiol (2002) 0.87
Medical planning and response for a nuclear detonation: a practical guide. Biosecur Bioterror (2012) 0.87
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87
The transposase domain protein Metnase/SETMAR suppresses chromosomal translocations. Cancer Genet Cytogenet (2010) 0.86
Scarce resources for nuclear detonation: project overview and challenges. Disaster Med Public Health Prep (2011) 0.86
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biol Blood Marrow Transplant (2008) 0.86
BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res (2012) 0.86
Medical response to a nuclear detonation: creating a playbook for state and local planners and responders. Disaster Med Public Health Prep (2011) 0.85
Development of automated quality reporting: aligning local efforts with national standards. AMIA Annu Symp Proc (2010) 0.84
Malpractice risk in ambulatory settings: an increasing and underrecognized problem. JAMA (2011) 0.83
Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One (2012) 0.80
Medical management of radiation victims in the United States. Health Phys (2010) 0.80
Assessing surge capacity for radiation victims with marrow toxicity. Biol Blood Marrow Transplant (2010) 0.79
Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther (2006) 0.79
Nosocomial central venous catheter infections among patients with different types of cancer. Infect Control Hosp Epidemiol (2002) 0.79
Using the model of resource and time-based triage (MORTT) to guide scarce resource allocation in the aftermath of a nuclear detonation. Disaster Med Public Health Prep (2011) 0.79
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol (2014) 0.78
Public health and medical preparedness for a nuclear detonation: the nuclear incident medical enterprise. Health Phys (2015) 0.78
Health care system planning for and response to a nuclear detonation. Disaster Med Public Health Prep (2011) 0.77
Hepatitis C virus infection does not preclude standard breast cancer-directed therapy. Clin Breast Cancer (2009) 0.77
Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant (2006) 0.76
Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling. Cell Commun Signal (2013) 0.75
Progress in infectious disease and immunology. JAMA (2011) 0.75
New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. Expert Opin Pharmacother (2005) 0.75
Frontal headache. JAMA (2011) 0.75
Drugs for diabetes. Treat Guidel Med Lett (2005) 0.75
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun (2017) 0.75
Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making. Disaster Med Public Health Prep (2011) 0.75
Malaria 2007--progressing research, persisting challenges. JAMA (2007) 0.75